1. Wang A.Y., Wang M., Woo J., Law M.C., Chow K.M., Li P.K., Lui S.F., Sanderson J.E.. A novel association between residual renal function and left ventricular hypertrophy in peritoneal dialysis patients.
Kidney Int 62:2002;639–647.
2. Wang A.Y., Wang M., Woo J., Lam C.W., Lui S.F., Li P.K., Sanderson J.E.. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients.
J Am Soc Nephrol 15:2004;2186–2194.
3. Bragg-Gresham J.L., Fissell R.B., Mason N.A., Bailie G.R., Gillespie B.W., Wizemann V., Cruz J.M., Akiba T., Kurokawa K., Ramirez S., Young E.W.. Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS).
Am J Kidney Dis 49:2007;426–431.
4. Shafi T., Jaar B.G., Plantinga L.C., Fink N.E., Sadler J.H., Parekh R.S., Powe N.R., Coresh J.. Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) study.
Am J Kidney Dis 56:2010;348–358.
5. Morduchowicz G., Winkler J., Zabludowski J.R., Boner G.. Effects of residual renal function in haemodialysis patients.
Int Urol Nephrol 26:1994;125–131.
6. Bammens B., Evenepoel P., Verbeke K., Vanrenterghem Y.. Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms.
Kidney Int 64:2003;2238–2243.
7. Miyamoto K., Segawa H., Ito M., Kuwahata M.. Physiological regulation of renal sodium-dependent phosphate cotransporters.
Jpn J Physiol 54:2004;93–102.
8. Murer H., Hernando N., Forster I., Biber J.. Proximal tubular phosphate reabsorption: molecular mechanisms.
Physiol Rev 80:2000;1373–1409.
9. Baum M., Schiavi S., Dwarakanath V., Quigley R.. Effect of fibroblast growth factor-23 on phosphate transport in proximal tubules.
Kidney Int 68:2005;1148–1153.
10. Daugirdas J.T.. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error.
J Am Soc Nephrol 4:1993;1205–1213.
11. Bergström J., Heimbürger O., Lindholm B.. Calculation of the protein equivalent of total nitrogen appearance from urea appearance. Which formulas should be used?
Perit Dial Int 18:1998;467–473.
12. Ogawa T., Ishida H., Matsuda N., Fujiu A., Matsuda A., Ito K., Ando Y., Nitta K.. Simple evaluation of aortic arch calcification by chest radiography in hemodialysis patients.
Hemodial Int 13:2009;301–306.
13. Viaene L., Bammens B., Meijers B.K., Vanrenterghem Y., Vanderschueren D., Evenepoel P.. Residual renal function is an independent determinant of serum FGF-23 levels in dialysis patients.
Nephrol Dial Transplant 27:2012;2017–2022.
14. Penne E.L., van der Weerd N.C., Grooteman M.P., Mazairac A.H., van den Dorpel M.A., Nubé M.J., Bots M.L., Levesque R., Ter Wee P.M., Blankestijn P.J.; CONTRAST Investigators. Role of residual renal function in phosphate control and anemia management in chronic hemodialysis patients.
Clin J Am Soc Nephrol 6:2011;281–289.
15. Liu S., Quarles L.D.. How fibroblast growth factor 23 works.
J Am Soc Nephrol 18:2007;1637–1647.
16. Wang M., You L., Li H., Lin Y., Zhang Z., Hao C., Chen J.. Association of circulating fibroblast growth factor-23 with renal phosphate excretion among hemodialysis patients with residual renal function.
Clin J Am Soc Nephrol 8:2013;116–125.
17. Ketteler M., Biggar P.H., Liangos O.. FGF23 antagonism: the thin line between adaptation and maladaptation in chronic kidney disease.
Nephrol Dial Transplant 28:2013;821–825.
18. Prié D., Ureña Torres P., Friedlander G.. Latest findings in phosphate homeostasis.
Kidney Int 75:2009;882–889.
19. Kuro-o M.. Klotho in health and disease.
Curr Opin Nephrol Hypertens 21:2012;362–368.
20. Beddhu S., Ramkumar N., Pappas L.M.. Normalization of protein intake by body weight and the associations of protein intake with nutritional status and survival.
J Ren Nutr 15:2005;387–397.
21. Oliveira C.M., Kubrusly M., Mota R.S., Silva C.A., Oliveira V.N.. Malnutrition in chronic kidney failure: what is the best diagnostic method to assess?
J Bras Nefrol 32:2010;55–68.
22. Silver J.. FGF23 and PTH-double agents at the heart of CKD.
Nephrol Dial Transplant 27:2012;1715–1720.
23. Mirza M.A., Hansen T., Johansson L., Ahlström H., Larsson A., Lind L., Larsson T.E.. Relationship between circulatingFGF23 and total body atherosclerosis in the community.
Nephrol Dial Transplant 24:2009;3125–3131.
24. Shroff R.. Phosphate is a vascular toxin.
Pediatr Nephrol 28:2013;583–593.
25. Shroff R.C., Donald A.E., Hiorns M.P., Watson A., Feather S., Milford D., Ellins E.A., Storry C., Ridou D., Deanfield J., Rees L.. Mineral metabolism and vascular damage in children on dialysis.
J Am Soc Nephrol 18:2007;2996–3003.
26. Dellegrottaglie S., Sanz J., Rajagopalan S.. Vascular calcification in patients with chronic kidney disease.
Blood Purif 24:2006;56–62.
27. Abbadi M., Giachelli C.M.. Mechanism of vascular calcification.
Adv Chronic Kidney Dis 14:2007;54–56.
28. Osorio A., Ortega E., Torres J.M., Sanchez P., Ruiz-Requena E.. Biochemical markers of vascular calcification in elderly hemodialysis patients.
Mol Cell Biochem 374:2013;21–27.
29. Singh M., Sharma P.K., Garg V.K., Mondal S.C., Singh A.K., Kumar N.. Role of fetuin-A in atherosclerosis associated with diabetic patients.
J Pharm Pharmacol 64:2012;1703–1708.